Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
19.99
-0.08 (-0.40%)
At close: Mar 9, 2026, 4:00 PM EDT
20.17
+0.18 (0.90%)
After-hours: Mar 9, 2026, 5:01 PM EDT
Apellis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 466.23 | 411.29 | 351.19 | 551.8 | 640.19 | Upgrade
|
| Short-Term Investments | 1.55 | 4.85 | 4.35 | 6.51 | 61.04 | Upgrade
|
| Cash & Short-Term Investments | 467.79 | 416.14 | 355.54 | 558.31 | 701.23 | Upgrade
|
| Cash Growth | 12.41% | 17.04% | -36.32% | -20.38% | -20.10% | Upgrade
|
| Accounts Receivable | 369.16 | 271.72 | 224.5 | 29.17 | 80.1 | Upgrade
|
| Other Receivables | - | - | - | 8.71 | - | Upgrade
|
| Receivables | 369.16 | 271.72 | 224.5 | 37.88 | 80.1 | Upgrade
|
| Inventory | 144.76 | 82.48 | 162.66 | 99.7 | 24 | Upgrade
|
| Prepaid Expenses | 9.52 | 9.51 | 8.59 | 7.18 | 5.17 | Upgrade
|
| Restricted Cash | 1.53 | 1.32 | 1.11 | 1.27 | 1.56 | Upgrade
|
| Other Current Assets | 22.1 | 7.78 | 13.93 | 15.18 | 11.98 | Upgrade
|
| Total Current Assets | 1,015 | 788.95 | 766.33 | 719.52 | 824.05 | Upgrade
|
| Property, Plant & Equipment | 19.9 | 19.04 | 21.09 | 24.9 | 26.08 | Upgrade
|
| Long-Term Accounts Receivable | - | - | - | 15 | 30 | Upgrade
|
| Other Long-Term Assets | 40.51 | 77.06 | 1.31 | 0.8 | 1.64 | Upgrade
|
| Total Assets | 1,075 | 885.05 | 788.73 | 760.22 | 881.77 | Upgrade
|
| Accounts Payable | 56.8 | 38.57 | 37.52 | 37.34 | 16.91 | Upgrade
|
| Accrued Expenses | 166.05 | 140.18 | 127.81 | 95.14 | 103.24 | Upgrade
|
| Current Portion of Long-Term Debt | 93.66 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 7.09 | 6.75 | 6.44 | 5.63 | 4.12 | Upgrade
|
| Other Current Liabilities | - | - | 75.83 | 29.5 | 7.58 | Upgrade
|
| Total Current Liabilities | 323.6 | 185.51 | 247.59 | 167.61 | 131.85 | Upgrade
|
| Long-Term Debt | 361.66 | 452.83 | 93.03 | 92.74 | 189.02 | Upgrade
|
| Long-Term Leases | 11.95 | 10.2 | 11.45 | 14.35 | 17.08 | Upgrade
|
| Other Long-Term Liabilities | 7.9 | 7.97 | 242.13 | 315.65 | 345.15 | Upgrade
|
| Total Liabilities | 705.11 | 656.51 | 594.21 | 590.35 | 683.1 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 3,385 | 3,267 | 3,036 | 2,480 | 1,857 | Upgrade
|
| Retained Earnings | -3,013 | -3,035 | -2,837 | -2,309 | -1,657 | Upgrade
|
| Comprehensive Income & Other | -2.1 | -3.31 | -3.54 | -0.88 | -2.09 | Upgrade
|
| Total Common Equity | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 | Upgrade
|
| Shareholders' Equity | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 | Upgrade
|
| Total Liabilities & Equity | 1,075 | 885.05 | 788.73 | 760.22 | 881.77 | Upgrade
|
| Total Debt | 474.36 | 469.78 | 110.93 | 112.71 | 210.22 | Upgrade
|
| Net Cash (Debt) | -6.57 | -53.65 | 244.61 | 445.59 | 491.01 | Upgrade
|
| Net Cash Growth | - | - | -45.10% | -9.25% | -1.78% | Upgrade
|
| Net Cash Per Share | -0.05 | -0.43 | 2.06 | 4.20 | 5.82 | Upgrade
|
| Filing Date Shares Outstanding | 127.83 | 125.52 | 120.58 | 111.29 | 97.73 | Upgrade
|
| Total Common Shares Outstanding | 126.62 | 124.5 | 119.56 | 110.77 | 97.52 | Upgrade
|
| Working Capital | 691.24 | 603.45 | 518.74 | 551.91 | 692.2 | Upgrade
|
| Book Value Per Share | 2.92 | 1.84 | 1.63 | 1.53 | 2.04 | Upgrade
|
| Tangible Book Value | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 | Upgrade
|
| Tangible Book Value Per Share | 2.92 | 1.84 | 1.63 | 1.53 | 2.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.